	WuXi STA, a subsidiary of WuXi AppTec, announced the opening of its new large-scale oligonucleotide API manufacturing facility in Changzhou, China on Jan. 3, 2020.

, the new site can manufacture oligonucleotide APIs up to 1 mol/synthesis run, which will further expand the company’s ability to deliver new oligonucleotide therapies to market, according to a company press release. The facility can also provide services for small molecules, peptide process R&D, and manufacturing from laboratory to commercial scales.

	“By leveraging our small-molecule CMC (Chemical, Manufacturing, and Control) technology and capability platform as well as global standard quality system, WuXi STA provides a robust one-stop shop for oligonucleotide innovators. The opening of this large-scale manufacturing facility will empower more global partners to expedite the development and commercialization of oligonucleotide drugs to benefit patients worldwide,” said Dr. Minzhang Chen, CEO of WuXi STA, in the press release.

Facility Design and Engineering

Manufacturing

PharmTech News

Supplier News

The new site can manufacture oligonucleotide APIs at large scale.